Journal of Shanghai University >
Gene therapy for cardiovascular disease
Received date: 2016-04-19
Online published: 2016-06-30
Gene therapy shows great promise in the treatment of both inherited and acquired cardiovascular diseases. Identification of key molecule players in pathophysiology of cardiovascular disease and development of human disease genomic research lead to encouraging preclinical gene therapy studies in animal models. However, the presence of cellular immune responses, insufficient gene expression level and overall limited in vivo gene transduction efficiencies have hampered the translational progress to clinical use of gene therapy. In recent years, improvements in gene delivery system and discovery of advanced genome editing technologies open new therapeutic perspectives, with clustered regularly interspaced short palindromic repeats (CRISRP)/Cas9 genome editing technology already being successfully used in animal models to treat hypercholesterolemia. Further improvement in gene delivery efficiency, increase in targeting specificity of genome editing tools, and establishment of experimental systems for a thorough analysis of potential safety problems would help eventually bring gene therapy for heart disease to reality. In this review, recent advances in the use of different delivery vectors and CRISPR/Cas9 genome editing technology in gene therapy research to treat cardiovascular diseases are discussed.
DING Qiurong, CHEN Yanhao . Gene therapy for cardiovascular disease[J]. Journal of Shanghai University, 2016 , 22(3) : 270 -279 . DOI: 10.3969/j.issn.1007-2861.2016.03.013
[1] Mozaffarian D, Benjamin E J, Go A S, et al. Heart disease and stroke statistics—2016 update a report from the American Heart Association [J]. Circulation, 2016, 133(4): 447-545.
[2] Gheorghiade M, Pang P S. Acute heart failure syndromes [J]. J Am Coll Cardiol, 2009, 53(7): 557-573.
[3] Tilemann L, Ishikawa K, Weber T, et al. Gene therapy for heart failure [J]. Circ Res, 2012, 110(5): 777-793.
[4] Yerevanian A, Yerevanian A, Hajjar R J. Progress in gene therapy for heart failure [J]. J Cardiovasc Pharm, 2014, 63(2): 95-106.
[5] Gao M H, Lai N C, Miyanohara A, et al. Intravenous adeno-associated virus serotype 8 encoding urocortin-2 provides sustained augmentation of left ventricular function in mice [J].
Hum Gene Ther, 2013, 24(9): 777-785.
[6] Lai N C, Tang T, Gao M H, et al. Improved function of the failing rat heart by regulated expression of insulin-like growth factor Ⅰvia intramuscular gene transfer [J]. Hum Gene Ther,
2012, 23(3): 255-261.
[7] Ding Q R, Strong A, Patel K M, et al. Permanent alteration of PCSK9 with in vivo CRISPRCas9 genome editing [J]. Circ Res, 2014, 115(5): 488-492.
[8] Su C H, Wu Y J, Wang H H, et al. Nonviral gene therapy targeting cardiovascular system [J]. Am J Physiol Heart C, 2012, 303(6): H629-H638.
[9] Gyongyosi M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia—subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study [J]. Circulation, 2005, 112(9): 1157-1165.
[10] Scimia M C, Cannavo A, KochWJ. Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium [J]. Expert Rev Cardiovasc Ther, 2013, 11(8): 999-1013.
[11] Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery [J]. Annu Rev Biomed Eng, 2007, 9: 415-447.
[12] Fujii H, Sun Z, Li S H, et al. Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice [J]. JACC Cardiovasc Imaging, 2009, 2(7): 869-879.
[13] Fujii H, Li S H, Wu J, et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair [J]. Eur Heart J, 2011, 32(16): 2075-2084.
[14] Gill S L, O’neill H, McCoy R J, et al. Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro
model [J]. Technol Health Care, 2014, 22(1): 37-51.
[15] Petrus I, Chuah M, Vandendriessche T. Gene therapy strategies for hemophilia: benefits versus risks [J]. J Gene Med, 2010, 12(10): 797-809.
[16] Kay M A. State-of-the-art gene-based therapies: the road ahead [J]. Nat Rev Genet, 2011, 12(5): 316-328.
[17] Schneider C K, Salmikangas P, Jilma B, et al. Challenges with advanced therapy medicinal products and how to meet them [J]. Nat Rev Drug Disc, 2010, 9(3): 195-201.
[18] Mingozzi F, High K A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy [J]. Blood, 2013, 122(1): 23-36.
[19] Wasala N B, Shin J H, Duan D S. The evolution of heart gene delivery vectors [J]. J Gene Med, 2011, 13(10): 557-565.
[20] Parker A L, Nicklin S A, Baker A H. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications [J]. Curr Opin Mol Ther, 2008, 10(5):
439-448.
/
| 〈 |
|
〉 |
